Treatment of limited-stage small cell lung cancer: recent progress and future directions

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Small cell lung cancer (SCLC) is a common, largely preventable malignancy seen almost exclusively in smokers. Since the late 1960s, it has been recognized that SCLC is a systemic process that is not curable with surgery or thoracic radiotherapy alone. Accordingly, these patients are typically treated with combination chemotherapy irrespective of stage at diagnosis. Unfortunately, patients with extensive stage disease are rarely cured, even with aggressive treatment. On the other hand, patients with limited-stage disease sometimes experience long-term progression-free survival with chemotherapy with or without thoracic radiotherapy. Of the more than 40 000 cases of SCLC that will be diagnosed in the United States in 1992, approximately 25-50% will have limited-stage disease. Thus, as many as 20 000 patients have a potentially curable malignancy. Definite progress has been made in the treatment of limited-stage SCLC.

Original languageEnglish (US)
JournalLung Cancer
Volume9
Issue numberSUPPL. 1
DOIs
StatePublished - 1993

Fingerprint

Small Cell Lung Carcinoma
Radiotherapy
Therapeutics
Combination Drug Therapy
Thoracic Surgery
Disease-Free Survival
Neoplasms
Thorax
Drug Therapy
Direction compound

Keywords

  • Small cell lung cancer

ASJC Scopus subject areas

  • Oncology

Cite this

Treatment of limited-stage small cell lung cancer : recent progress and future directions. / Johnson, David H.

In: Lung Cancer, Vol. 9, No. SUPPL. 1, 1993.

Research output: Contribution to journalArticle

@article{058e262275dd4bf19bf20b8b1e332623,
title = "Treatment of limited-stage small cell lung cancer: recent progress and future directions",
abstract = "Small cell lung cancer (SCLC) is a common, largely preventable malignancy seen almost exclusively in smokers. Since the late 1960s, it has been recognized that SCLC is a systemic process that is not curable with surgery or thoracic radiotherapy alone. Accordingly, these patients are typically treated with combination chemotherapy irrespective of stage at diagnosis. Unfortunately, patients with extensive stage disease are rarely cured, even with aggressive treatment. On the other hand, patients with limited-stage disease sometimes experience long-term progression-free survival with chemotherapy with or without thoracic radiotherapy. Of the more than 40 000 cases of SCLC that will be diagnosed in the United States in 1992, approximately 25-50{\%} will have limited-stage disease. Thus, as many as 20 000 patients have a potentially curable malignancy. Definite progress has been made in the treatment of limited-stage SCLC.",
keywords = "Small cell lung cancer",
author = "Johnson, {David H.}",
year = "1993",
doi = "10.1016/0169-5002(93)90001-E",
language = "English (US)",
volume = "9",
journal = "Lung Cancer",
issn = "0169-5002",
publisher = "Elsevier Ireland Ltd",
number = "SUPPL. 1",

}

TY - JOUR

T1 - Treatment of limited-stage small cell lung cancer

T2 - recent progress and future directions

AU - Johnson, David H.

PY - 1993

Y1 - 1993

N2 - Small cell lung cancer (SCLC) is a common, largely preventable malignancy seen almost exclusively in smokers. Since the late 1960s, it has been recognized that SCLC is a systemic process that is not curable with surgery or thoracic radiotherapy alone. Accordingly, these patients are typically treated with combination chemotherapy irrespective of stage at diagnosis. Unfortunately, patients with extensive stage disease are rarely cured, even with aggressive treatment. On the other hand, patients with limited-stage disease sometimes experience long-term progression-free survival with chemotherapy with or without thoracic radiotherapy. Of the more than 40 000 cases of SCLC that will be diagnosed in the United States in 1992, approximately 25-50% will have limited-stage disease. Thus, as many as 20 000 patients have a potentially curable malignancy. Definite progress has been made in the treatment of limited-stage SCLC.

AB - Small cell lung cancer (SCLC) is a common, largely preventable malignancy seen almost exclusively in smokers. Since the late 1960s, it has been recognized that SCLC is a systemic process that is not curable with surgery or thoracic radiotherapy alone. Accordingly, these patients are typically treated with combination chemotherapy irrespective of stage at diagnosis. Unfortunately, patients with extensive stage disease are rarely cured, even with aggressive treatment. On the other hand, patients with limited-stage disease sometimes experience long-term progression-free survival with chemotherapy with or without thoracic radiotherapy. Of the more than 40 000 cases of SCLC that will be diagnosed in the United States in 1992, approximately 25-50% will have limited-stage disease. Thus, as many as 20 000 patients have a potentially curable malignancy. Definite progress has been made in the treatment of limited-stage SCLC.

KW - Small cell lung cancer

UR - http://www.scopus.com/inward/record.url?scp=0027268511&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027268511&partnerID=8YFLogxK

U2 - 10.1016/0169-5002(93)90001-E

DO - 10.1016/0169-5002(93)90001-E

M3 - Article

AN - SCOPUS:0027268511

VL - 9

JO - Lung Cancer

JF - Lung Cancer

SN - 0169-5002

IS - SUPPL. 1

ER -